Table I.
Characteristics of COVID-19 cases and controls in patients with psoriatic disease
| Patient characteristic | COVID-19 cases N=58 |
Patients with severe COVID-19 N=11 |
Controls N = 115 |
P value§ |
|---|---|---|---|---|
| Age | 52.8 | 60.6 | 57.1 | .058∗ |
| Gender (N, % Female) | 30 (51.7%) | 7 (9.1%) | 63 (54.8%) | .826∗ |
| BMI | 29.7 | 34.5 | 26.4 | .010∗,† |
| Race (N, %) | .046∗,† | |||
| White | 44 (75.9%) | 7 (63.6%) | 104 (91.3%) | |
| Black | 1 (1.7%) | 1 (9.1%) | 1 (0.9%) | |
| Asian | 8 (13.8%) | 3 (27.3%) | 6 (5.2%) | |
| Other | 4 (6.9%) | 0 (0%) | 1 (0.9%) | |
| Psoriasis (N, %) | 35 (65.5%) | 86 (75.8%) | .075∗ | |
| Psoriatic arthritis (Number, %) | 42 (72.4%) | 8 (72.7%) | 78 (67.8%) | .658∗ |
| Severity of psoriatic disease | .641∗ | |||
| Remission/Mild (%) | 11 (19.0%) | 1 (9.1%) | 15 (13.0%) | |
| Mild | 25 (43.1%) | 4 (36.4%) | 53 (46.1%) | |
| Moderate | 17 (29.3%) | 4 (36.4%) | 40 (34.9%) | |
| Severe | 5 (8.6%) | 2 (18.2%) | 7 (6.1%) | |
| Psoriatic disease therapy (Number, %) | ||||
| Methotrexate | 11 (19.0%) | 2 (18.2%) | 25 (21.7%) | .8213∗ |
| Oral glucocorticoids | 2 (3.4%) | 0 (0%) | 4 (3.5%) | .99∗ |
| Apremilast | 3 (5.2%) | 1 (9.1%) | 8 (7.0%) | .731∗ |
| Any biologic or JAK inhibitor | 42 (72.4%) | 7 (63.6%) | 65 (56.5%) | .062∗ |
| TNF-inhibitors | 13 (22.4%) | 4 (36.4%) | 29 (25.2%) | 1.00∗ |
| IL-17 blockers | 15 (25.9%) | 2 (18.2%) | 23 (20.0%) | .288∗ |
| IL-12/23 or IL-23 blockers | 11 (19.0%) | 1 (9.1%) | 7 (6.1%) | .008∗,† |
| JAK inhibitors | 1 (1.7%) | 1 (9.1%) | 6 (5.2%) | .426∗ |
| Comorbidity | ||||
| CHF (N, %) | 4 (6.9%) | 1 (9.1%) | 0 (0%) | N/A‡ |
| HTN | 11 (19.0%) | 4 (36.4%) | 7 (6.1%) | .019∗,† |
| DM2 | 13 (11.3%) | 2 (18.2%) | 8 (13.8%) | .821∗ |
| COPD§ | 2 (1.7%) | 1 (9.1%) | 2 (3.4%) | .6027∗ |
| Asthma | 10 (8.7%) | 1 (9.1%) | 9 (15.5%) | .2726∗ |
| CKD | 1 (1.6%) | 0 (0%) | 1 (0.9%) | 1.00∗ |
| Liver disease | 2 (3.4%) | 0 (0%) | 0 (0%) | N/A‡ |
| Obesity | 19 (32.8%) | 5 (45.5%) | 25 (21.7%) | .1657∗ |
BMI, Body mass index; CHF, congestive heart faliure; CKD; chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM2, type 2 diabetes mellitus; HTN, hypertension; IL, interleukin; JAK, janus kinase; TNF, tumor necrosis factor.
∗
P value for all COVID-19 cases vs. controls.
†
P value for severe COVID-19 vs. controls or mild COVID-19.
‡
No P values can be calculated when the category has 0 events.
§
Reported P values are not adjusted for multiple comparisons.